CG Oncology (CGON) closed at $75.99 on November 6, 2026, up 17.3% from the previous close, on volume of 3,337,400 shares (30-day average 948,073).
Data as of November 6, 2026.
6-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 4, 2026 | Call with Delta Hedge | 20-Nov-26 75 C +250,000 Stock | 6,250 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 6, 2026. See the 10 largest for 30, 60 and 90 days
CG Oncology: PIVOT-006 Readout and 2026 Catalysts Support Buy Rating
TipRanks (Fri, 6-Nov 5:15 PM ET)
Buy Rating Reaffirmed on Cretostimogene’s Upcoming Phase 3 Readout; $100 Price Target Unchanged
TipRanks (Fri, 6-Nov 5:15 PM ET)
CG Oncology GAAP EPS of -$0.64 beats by $0.20, revenue of $1.6M beats by $1.07M
Seeking Alpha News (Fri, 6-Nov 8:42 AM ET)
CG Oncology Reports Third Quarter 2026 Financial Results and Provides Business Updates
Globe Newswire (Fri, 6-Nov 8:15 AM ET)
Globe Newswire (Tue, 13-Oct 8:00 AM ET)
Kuehn Law Encourages Investors of CG Oncology, Inc. to Contact Law Firm
PRNewswire (Mon, 12-Oct 9:32 PM ET)
CG Oncology to Present at Upcoming Investor Conferences in September
Globe Newswire (Wed, 2-Sep 8:00 AM ET)
CG Oncology Bolsters Cash Position to $1.1 Billion While Advancing Multiple Clinical Milestones
Market Chameleon (Fri, 8-May 5:24 AM ET)
Market Chameleon (Fri, 9-Jan 5:30 AM ET)
Market Chameleon (Fri, 9-Jan 4:39 AM ET)
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
CG Oncology trades on the NASDAQ stock market under the symbol CGON.
As of November 6, 2026, CGON stock price climbed to $75.99 with 3,337,400 million shares trading.
CGON has a beta of 0.47, meaning it tends to be less sensitive to market movements. CGON has a correlation of 0.01 to the broad based SPY ETF.
CGON has a market cap of $6.74 billion. This is considered a Mid Cap stock.
Last quarter CG Oncology reported $1 million in Revenue and -$.90 earnings per share. This beat revenue expectation by $325,208 and missed earnings estimates by -$.25.
The top ETF exchange traded funds that CGON belongs to (by Net Assets): VTI, VB, IWM, XBI, VBK.
CGON has outperformed the market in the last year with a price return of +91.5% while the SPY ETF gained +10.8%. CGON has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +1.5% and +23.1%, respectively, while the SPY returned -4.1% and -3.2%, respectively.
CGON support price is $62.99 and resistance is $66.62 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CGON shares will trade within this expected range on the day.
